Asian Value Stocks Estimated Below Intrinsic Worth In August 2026

As of August 2026, Asian markets have been navigating a complex landscape marked by geopolitical tensions and fluctuating commodity prices, which have contributed to investor caution across the region. Despite these challenges, opportunities arise for discerning investors seeking value stocks that may be trading below their intrinsic worth. Identifying such stocks requires careful analysis of fundamentals and market conditions, offering potential for growth when broader economic factors stabilize.

Top 10 Undervalued Stocks Based On Cash Flows In Asia

Name	Current Price	Fair Value (Est)	Discount (Est)
Winbond Electronics (TWSE:2344)	NT$177.00	NT$348.89	49.3%
Winall Hi-tech Seed (SZSE:300087)	CN¥5.50	CN¥10.84	49.3%
Techwing (KOSDAQ:A089030)	₩46650.00	₩91382.45	49%
SK oceanplantLtd (KOSE:A100090)	₩13000.00	₩25468.56	49%
Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990)	HK$523.00	HK$1045.89	50%
Sansha Electric ManufacturingLtd (TSE:6882)	¥1195.00	¥2342.30	49%
Nanya Technology (TWSE:2408)	NT$501.00	NT$988.30	49.3%
Japan Eyewear Holdings (TSE:5889)	¥2570.00	¥5054.56	49.2%
HyVision System (KOSDAQ:A126700)	₩11500.00	₩22924.18	49.8%
BEAUTY GARAGE (TSE:3180)	¥1573.00	¥3106.92	49.4%

Click here to see the full list of 219 stocks from our Undervalued Asian Stocks Based On Cash Flows screener.

Here's a peek at a few of the choices from the screener.

Zylox-Tonbridge Medical Technology (SEHK:2190)

Overview: Zylox-Tonbridge Medical Technology Co., Ltd. is a medical device company that offers neuro- and peripheral-vascular interventional devices in China and internationally, with a market cap of HK$6.95 billion.

Operations: The company generates revenue from the provision of interventional medical devices focused on neurovascular and peripheral-vascular applications in both domestic and international markets.

Estimated Discount To Fair Value: 48.2%

Zylox-Tonbridge Medical Technology is trading at HK$20.98, significantly below its estimated future cash flow value of HK$40.52, highlighting potential undervaluation. Recent earnings showed strong growth with net income reaching CNY 181.71 million for the first half of 2026, up from CNY 121.2 million a year ago. Earnings are forecast to grow at a robust rate of 27.3% per year, outpacing the Hong Kong market's growth expectations, despite a relatively low expected return on equity of 12.8%.

• Our expertly prepared growth report on Zylox-Tonbridge Medical Technology implies its future financial outlook may be stronger than recent results.
• Take a closer look at Zylox-Tonbridge Medical Technology's balance sheet health here in our report.

SMS (TSE:2175)

Overview: SMS Co., Ltd. operates in the nursing care, medical care, career, healthcare, and elderly care sectors by providing information infrastructure services both in Japan and internationally, with a market cap of ¥194.56 billion.

Operations: The company's revenue segments include nursing care, medical care, career services, healthcare, and elderly care fields in Japan and internationally.

Estimated Discount To Fair Value: 28.3%

SMS Co., Ltd. is trading at ¥2,370, well below its estimated future cash flow value of ¥3,304.76, suggesting significant undervaluation. Despite a slight dip in net income for Q1 2026 compared to the previous year, revenue increased to ¥20.21 billion from ¥18.67 billion. Earnings are projected to grow by 55% annually over three years with an expected high return on equity of 23.7%, indicating strong potential for profitability and growth above market averages.

• Our growth report here indicates SMS may be poised for an improving outlook.
• Unlock comprehensive insights into our analysis of SMS stock in this financial health report.

Vector (TSE:6058)

Overview: Vector Inc. operates in the public relations and advertising sectors across Japan, China, and internationally with a market cap of ¥91.60 billion.

Operations: The company's revenue is primarily derived from PR and Advertising at ¥35.97 billion, followed by Direct Marketing at ¥17.16 billion, Press Release Distribution at ¥9.77 billion, HR services at ¥2.54 billion, and Investment activities contributing ¥719 million.

Estimated Discount To Fair Value: 38.1%

Vector Inc. trades at ¥1,953, significantly below its estimated future cash flow value of ¥3,156.26, indicating potential undervaluation. Recent earnings showed a strong increase with net income rising to ¥1.98 billion from ¥767 million year-over-year. The company revised its Q2 guidance upward due to better-than-expected first-quarter results and anticipates higher profits in the first half of 2026 while maintaining full-year forecasts unchanged, reflecting robust revenue growth prospects above the market average.

• According our earnings growth report, there's an indication that Vector might be ready to expand.
• Dive into the specifics of Vector here with our thorough financial health report.

Where To Now?

• Investigate our full lineup of 219 Undervalued Asian Stocks Based On Cash Flows right here.
• Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks.
• Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world.

Ready For A Different Approach?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com